A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D
详细信息    查看全文
文摘
Uterine leiomyosarcomas are poor prognosis tumors with few effective treatments. Aurora-A kinase deregulations are common in uterine leiomyosarcoma. Alisertib monotherapy was not active in advanced/recurrent uterine leiomyosarcoma.
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.